GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » Cash-to-Debt

SER (Serina Therapeutics) Cash-to-Debt : 13.70 (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Serina Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Serina Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2024 was 13.70.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Serina Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for Serina Therapeutics's Cash-to-Debt or its related term are showing as below:

SER' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29   Med: 2.75   Max: 13.7
Current: 13.7

During the past 4 years, Serina Therapeutics's highest Cash to Debt Ratio was 13.70. The lowest was 0.29. And the median was 2.75.

SER's Cash-to-Debt is ranked better than
58.29% of 1484 companies
in the Biotechnology industry
Industry Median: 7.44 vs SER: 13.70

Serina Therapeutics Cash-to-Debt Historical Data

The historical data trend for Serina Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Serina Therapeutics Cash-to-Debt Chart

Serina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Cash-to-Debt
3.29 0.29 2.21 13.70

Serina Therapeutics Quarterly Data
Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 2.21 0.79 0.52 0.28 13.70

Competitive Comparison of Serina Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Serina Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Serina Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Serina Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Serina Therapeutics's Cash-to-Debt falls into.


;
;

Serina Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Serina Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=3.672 / (0 + 0.268)
=13.70

Serina Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=3.672 / (0 + 0.268)
=13.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Serina Therapeutics  (AMEX:SER) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Serina Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Serina Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Serina Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » Cash-to-Debt
Comparable Companies
FBRX ADAP STTK CTMX KRON GANX MGX ALVR ALGS DTIL VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
2BO:Germany
Address
601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Website
https://www.serinatherapeutics.com
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.